$0.85 0.00 (0%)
2/10/2012 4:00 PM

BioSante Pharmaceuticals, Inc. (NASDAQ:BPAX)

CAPS Rating: 2 out of 5

A biopharmaceutical company that licenses and develops hormone therapy products to treat men and women.

Results 1 - 20 of 47 : 1 2 3 Next »

Recs

0
Member Avatar Texans1014 (< 20) Submitted: 2/9/2012 10:02:28 AM : Outperform Start Price: $0.90 BPAX Score: -5.52

LibiGel, BPAX's product, received a positive safety rating, expect company to make profits. I'm buying!

Recs

1
Member Avatar usubanas (99.75) Submitted: 2/7/2012 10:00:53 AM : Underperform Start Price: $0.88 BPAX Score: +3.59

time to throw in the towel

Recs

0
Member Avatar Rajhi (57.69) Submitted: 2/7/2012 9:39:48 AM : Outperform Start Price: $0.68 BPAX Score: +24.34

Should be above 1$

Recs

0
Member Avatar seattle1218 (< 20) Submitted: 2/6/2012 7:31:31 PM : Outperform Start Price: $1.02 BPAX Score: -16.71

i got in at .67 and am happy I did. I am hoping for good news on feb. 14th. Trying to decide if I should sell before then?!

Recs

0
Member Avatar callumturcan (37.47) Submitted: 2/6/2012 7:29:44 PM : Outperform Start Price: $1.02 BPAX Score: -16.71

Oversold, a lot of short positions that need to exit(18.08m), and Bio-T-Gel FDA review date on February 14th, 2012. And GVAX is showing great potencial.

Recs

1
Member Avatar StockTraderG (45.18) Submitted: 2/6/2012 6:17:00 PM : Underperform Start Price: $0.68 BPAX Score: -23.29

OMG, BPAX has run up 40% since i initiated my red thumb, and it has run on complete fluff. This company is in the tank ever since the recent CRL, and if they try to climb out, I believe shareholders will be substantially diluted. Short-term, I'm obviously effed and I expect more Seeking Alpha BS articles in the near future. Long-term this stock is coming down. Way down.

Recs

0
Member Avatar ThirdWheelNeil (< 20) Submitted: 2/5/2012 4:46:56 PM : Outperform Start Price: $0.76 BPAX Score: +11.69

Way oversold on panic sell in December. Unintended results showing positive effectivenees ( 75% ) on preventing cardiovascular accidents in women. 90% chance of FDA approval Feb 14th ( possibly sooner ). Huge pipeline inc cancer drugs in late phase. Will shoot up to $5 or $6 ( could hit $10. )

Recs

2
Member Avatar acts20 (85.36) Submitted: 1/30/2012 9:45:49 PM : Outperform Start Price: $0.67 BPAX Score: +24.68

it looks like a pump and dump on yahoo boards

Recs

0
Member Avatar vincentjmack (< 20) Submitted: 1/29/2012 4:16:37 PM : Outperform Start Price: $0.65 BPAX Score: +27.97

T-gel should receive approval and any update on libigel will send this soaring

Recs

0
Member Avatar mdriver78 (27.26) Submitted: 1/12/2012 3:12:44 PM : Outperform Start Price: $0.51 BPAX Score: +62.29

Selling for less than cash!

Recs

0
Member Avatar Imhilion (56.43) Submitted: 1/11/2012 2:03:22 PM : Outperform Start Price: $0.52 BPAX Score: +57.98

Should rally as we approach Feb 14, High Risk High Reward FDA approval play

Recs

0
Member Avatar headyinvestor (47.71) Submitted: 1/10/2012 12:12:35 PM : Outperform Start Price: $0.57 BPAX Score: +45.35

bio-t gel approval

Recs

1
Member Avatar zzlangerhans (99.26) Submitted: 1/9/2012 8:13:27 PM : Outperform Start Price: $0.50 BPAX Score: +63.62

I'm still searching for that elusive CAPS multibagger, a quest which often causes me to hold my winners against my better judgement thereby losing everything I gained and more. Such was the case with BioSante, where I got in early and held my ground through a disastrous phase III data release. I expected the real battle of BioSante to come at the regulatory and commercialization level rather than the efficacy level, but so go my fortunes with binary catalysts.

I ditched an ugly losing score to refocus on the upcoming PDUFA for Bio-T-gel, postponed three months to February 14. It's hard to project much commercial success for yet another rub-on testosterone in a crowded market, but the drug is already partnered with Teva and stands a good chance of FDA approval. If it hadn't been for the Libigel smackdown, BioSante would probably be trading at a market cap over 100M just on the potential of Bio-T-gel. Hopefully I'll get the three bagger with BioSante that I missed the last time.

Recs

2
Member Avatar RXDOC73 (98.62) Submitted: 12/14/2011 1:36:14 PM : Outperform Start Price: $2.53 BPAX Score: -76.05

Takeover target

Recs

0
Member Avatar francisdeep1 (22.53) Submitted: 10/31/2011 1:47:15 AM : Outperform Start Price: $2.67 BPAX Score: -74.08

run before fda review nov.14,2011

Recs

0
Member Avatar JuanPeter (61.34) Submitted: 9/8/2011 4:52:17 PM : Outperform Start Price: $2.88 BPAX Score: -84.63

Got in at $2.45 a couple of days ago. Three co. presentations this month and safety results of Libigel in Q4 plus a PDUFA date of 11/14 for Bio T Gel are going to make this company an attractive candidate for a potential run-up.

Follow me on twitter @JPZaragoza1

Recs

0
Member Avatar DanishDynamite (< 20) Submitted: 7/22/2011 4:40:56 AM : Outperform Start Price: $3.70 BPAX Score: -76.88

Cell Genesys shareholders got screwed by management. With GVAX back on track BioSante should do well.

Recs

0
Member Avatar Olddognwtrx (< 20) Submitted: 7/14/2011 6:04:27 PM : Outperform Start Price: $3.70 BPAX Score: -79.05

Safety study closed, efficacy guaranteed, 4 million off label T scripts, in talks with "many many" potential buyers, 500 million very very conservative price. risk reward here is great.

Recs

0
Member Avatar zayy862 (< 20) Submitted: 7/4/2011 7:24:58 PM : Outperform Start Price: $2.95 BPAX Score: -71.59

I believe Libigel will get approved. Its already a 90% garuntee the FDA will approve it, and if they do it will be a sure monopoly since its the only product of its kind out. Not saying it will turn the company into the next Google, but it will definitely benefit the company

Recs

0
Member Avatar rockportfred (81.59) Submitted: 5/23/2011 11:24:18 AM : Outperform Start Price: $2.81 BPAX Score: -71.55

female sex stimuli

Results 1 - 20 of 47 : 1 2 3 Next »

Featured Broker Partners


Advertisement